T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category at the 12th World ADC Awards 2025. Selected from a highly competitive pool of global nominees, T-E Meds is one of six finalists to receive this distinguished honor. Since its launch in 2014, the World […]
T-E Meds Shortlisted for World ADC Awards – Best New Drug Developer Read More »
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection site reactions seen with current therapies.• Strong Pharmacodynamic Activity: Robust, dose-dependent reduction of disease biomarker IGF-1, with 83% of high-dose participants achieving a >20% reduction, confirming therapeutic potential.• Significant Market Potential: Positioned for the US$10 billion long-acting
On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning of a deep strategic collaboration in the field of innovative drug development, with the goal of jointly advancing the global pharmaceutical industry.Ms. Yang Rui, Co-CEO of Asymchem, and Dr. Hsin-Mao Chu, CEO of T-E Meds,
Website link: https://news.gbimonthly.com/tw/article/show.php?num=75729&page=1
Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide,” has been published in the prestigious Journal of Medicinal Chemistry. Led by Dr. Wun-Teng Wong, Manager of
Our latest research result is published in J. Med. Chem. Read More »
Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th January. Immunwork has developed two ultra-long-acting drugs: TE-8105 and TE-8214. TE-8105 primarily targets type 2 diabetes, obesity, and fatty liver disease, and is scheduled to complete Phase 2a clinical trials this year. TE-8214 focuses on
Immunwork 2025 Investor Meeting – Results Presentation Read More »
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to the contract, T-E Meds will receive a signing and licensing fee of NT$270 million (approximately USD 8.5 million) for granting the commercialization rights of the TE-1146 drug in Taiwan, Southeast Asia, New Zealand and the
T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146 Read More »
Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been honored with the 21st National Innovation Award – Enterprise Innovation Award. This prestigious recognition highlights the excellence of Immunwork’s platform technology and the promising potential drug candidates, earning high acclaim from both national and professional
Immunwork won the 21st National Innovation Award – Enterprise Innovation Award Read More »
The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang Exhibition Center. We are honored to be invited to showcase our booth in the InnoZone Innovation Technology Pavilion. You’re welcome to visit us and learn about our latest developments!
We will be participating in the 8th Taiwan Healthcare+ Expo Taiwan. Welcome to visit us Read More »
Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. Dr. Li will unravel the innovations behind our cutting-edge therapeutic peptides and ADC platform, highlighting the distinctive “Multi-Arm Linkers.”
Join our presentation at the ACCESS CHINA Partnering Forum Read More »
